Targeting MgrA-Mediated Virulence Regulation in Staphylococcus aureus  by Sun, Fei et al.
Chemistry & Biology
ArticleTargeting MgrA-Mediated Virulence Regulation
in Staphylococcus aureus
Fei Sun,1 Lu Zhou,1 Bing-Chuan Zhao,2 Xin Deng,1 Hoonsik Cho,4 Chengqi Yi,1 Xing Jian,1 Chun-Xiao Song,1
Chi-Hao Luan,3 Taeok Bae,4 Zigang Li,2,* and Chuan He1,*
1Department of Chemistry and Institute for Biophysical Dynamics, The University of Chicago, Chicago, IL 60637, USA
2Key Lab of Chemical Genomics, School of Chemical Biology & Biotechnology, Shenzhen Graduate School, Peking University,
Shenzhen 518055, China
3High Throughput Analysis Laboratory, Northwestern University, Evanston, IL 60208, USA
4Department of Microbiology and Immunology, Indiana University School of Medicine-Northwest, Gary, IN 46408, USA
*Correspondence: lizg@szpku.edu.cn (Z.L.), chuanhe@uchicago.edu (C.H.)
DOI 10.1016/j.chembiol.2011.05.014SUMMARY
Increasing antibiotic resistance in human pathogens
necessitates the development of new approaches
against infections. Targeting virulence regulation at
the transcriptional level represents a promising stra-
tegy yet to be explored. A global transcriptional regu-
lator, MgrA in Staphylococcus aureus, was identified
previously as a key virulence determinant. We have
performed a fluorescence anisotropy (FA)–based
high-throughput screen that identified 5, 5-methyle-
nedisalicylic acid (MDSA), which blocks the DNA
binding of MgrA. MDSA represses the expression
of a-toxin that is up-regulated by MgrA and activates
the transcription of protein A, a gene down-regulated
by MgrA. MDSA alters bacterial antibiotic suscepti-
bilities via an MgrA-dependent pathway. A mouse
model of infection indicated that MDSA could atten-
uate S. aureus virulence. This work is a rare demon-
stration of utilizing small molecules to block
protein-DNA interaction, thus tuning important bio-
logical regulation at the transcriptional level.
INTRODUCTION
Staphylococcus aureus is a common human pathogen that
causes a wide variety of diseases, ranging fromminor skin infec-
tions to life-threatening endocarditis, pneumonia, blood infec-
tions, and toxic shock syndrome (Archer, 1998; Lowy, 1998).
This pathogen can infect almost every tissue in the human
host. Its versatility is mostly due to the production of various viru-
lence factors, such as hemolysins, leukocidins, and immune
modulators. More troublesome, strategies that fight staphylo-
coccal infection have deteriorated in the past several decades
owing to the emergence of multiple methicillin-resistant strains
(MRSAs) andmore recent vancomycin-resistant strains.MRSAs,
which are isolated in up to 60% of community and 80% of
hospital infections, have rendered the entire class of b-lactam
antimicrobials obsolete as therapeutic agents (Centers for
Disease Control and Prevention, 2007). Although vancomycin1032 Chemistry & Biology 18, 1032–1041, August 26, 2011 ª2011 Elhas long been considered as the last resort therapy for MRSAs
(Fridkin et al., 2005), vancomycin-resistant strains with interme-
diate (VISAs) or full resistance (VRSAs) to vancomycin and other
glycopeptide inhibitors of cell wall synthesis have caused infec-
tions for which traditional antibiotic treatment have been in vain
(Chang et al., 2003; Walsh, 1993; Weigel et al., 2003).
Virulence suppression represents an alternative approach to
combating infections (Balaban et al., 1998; Gresham et al.,
2000; Ji et al., 1997). The mode of action of conventional antibi-
otics largely relies on targeting essential cellular functions, such
as DNA replication, protein synthesis, and cell wall synthesis.
Because of bactericidal (bacterial-killing) or bacteriostatic
(growth-inhibitory) effects, overuse of these antibiotics imposes
selective pressures on bacteria and thus leads to the emergence
of drug-resistant strains. Given that most virulence factors are
nonessential for bacteria, in principle, antimicrobial agents that
are designed for inhibiting microbial virulence without inhibiting
growth presumably exert less selective pressure for the genera-
tion of resistance (Clatworthy et al., 2007). The expression of
virulence factors is coordinately regulated by multiple two-
component systems and global transcription factors. MgrA in
particular plays a key role in the regulation of the expression of
major virulence factors in S. aureus (e.g., capsular polysaccha-
ride, protease, a-toxin, nuclease, and protein A) (Ingavale
et al., 2005; Luong et al., 2006; Truong-Bolduc et al., 2005).
MgrA is a member of the MarR (multiple antibiotic resistance
regulator)/SarA (staphylococcal accessory regulator A) family
proteins and controls expression of 350 genes (Luong et al.,
2006). We have shown that MgrA is critical for S. aureus patho-
genesis in vivo, and an mgrA mutant strain exhibits 1000–
10,000 fold virulence reduction in a mouse model of infection
(Chen et al., 2006). We have also revealed that MgrA acts as
a redox-switch via its sole and unique Cys12 to regulate gene
expression. Oxidation of this Cys leads to dissociation of the
oxidized MgrA from DNA and thus attenuation of the bacterial
virulence. The regulation of MgrA could also be affected by envi-
ronmental stimuli, as shown by a previous study in which the
transcriptional expression ofmgrAwas down-regulated by salic-
ylate (Riordan et al., 2007). Given the dramatic role MgrA plays in
S. aureus virulence, this transcription factor could be a feasible
target for developing antimicrobial drugs. Chemically inhibiting
DNA binding of MgrA could potentially diminish S. aureus viru-
lence. As proof of principle, we demonstrate here that smallsevier Ltd All rights reserved
Figure 1. High-Throughput Screening and
Hit Characterization Strategy
A fluorescence anisotropy–based assay using
a fluorescein-labeled DNA recognized by MgrA
was used in HTS (Z0 factor of 0.81). Compounds
displaying R50% inhibition on the MgrA-DNA
binding were selected as positive hits. The 94 hits
were subjected to a fluorescence-based thermal
shift assay to further probe their direct interactions
with MgrA. Four top hits were evaluated in
in vitro experiments, such as EMSA, to confirm
their activity in disrupting MgrA-DNA interaction.
MDSA, the most effective inhibitor for MgrA, was
applied to a series of in vivo characterizations
including transcriptional expression analysis on
virulence factors, antibiotic resistance assays, and
a murine abscess infection model. See also Fig-
ure S1.
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Small Molecules Inhibit MgrAmolecules identified from a high-throughput screen (HTS) are
able to disrupt the DNA binding of MgrA and that administration
of such a compound leads to a reduced staphylococcal infection
in a murine abscess model of infection.
RESULTS
Screening Inhibitors for MgrA
A fluorescence anisotropy (FA)–based biochemical assay
that monitors MgrA-DNA binding was optimized for HTS. The
DNA probe (50-TAAACAACAAGTTGTCCAAA-30) containing an
MgrA-binding box (AGTTGT) was synthesized and fluorescently
labeled with 6-carboxylfluorescein (Manna et al., 2004), a widely
used fluorophore with excitation at 494 nm and emission at
521 nm (see Figure S1A available online). According to the Perrin
equation, the FA value is proportional to the molecular volume
(molecular weight) of fluorescently labeled biomolecules. In this
case, the fluorescein-labeled DNA alone generates a small FA
value (0.8), whereas the formation of MgrA-DNA complex
increases the FA value up to 2.8. The binding affinity of MgrA
to this particular DNA probe was determined using this method
(Kd 0.14 mM) (Figure S1B). Translation of this assay into
a 96-well format plate yielded a Z0 factor of 0.81 with 20 nM
DNA and 400 nM MgrA, which is well above the value (0.5) sug-
gested for typical HTS assays (Figure S1C). A total of 88,564
compounds were screened in duplicate against the MgrA-DNA
interaction using the NSRB library. Among the small molecules
screened, 114 (0.13%) exhibited significant inhibition (R50%)
on the DNA binding of MgrA. Of these, 19 hits are from natural
product extracts and tentatively excluded from cherry picks
because of a lack of structural and composition information.Chemistry & Biology 18, 1032–1041, August 26, 2011 ªThe other 95 hits with confident struc-
tural information and purity were picked
for the subsequent validation and
characterization.
Although FA has been widely used to
study the interaction of biomolecules
and proven to be an effective method
for HTS, several caveats must be ac-
counted for when using this type ofscreen. First, the inherent fluorescent properties of test
compounds could interfere with the FA readout and produce
false-positive results. Second, in the screen to disrupt protein-
DNA interactions, some compounds could simply intercalate
into DNA and prevent the binding of MgrA. To rule out these
unwanted scenarios, initial screening hits were filtered by a
combination of cheminformatics (data analysis to exclude low-
confidence inhibitors and autofluorescent false-positive results),
the secondary screen based on the fluorescence-based thermal
shift assay, and biochemical and phenotypical characterization
of top hits in S. aureus (Figure 1). The fluorescence-based
thermal shift assay, which represents a general method for iden-
tification of inhibitors of target proteins from a number of hit
compounds, was used to verify the direct interaction between
MgrA and selected compounds (Lo et al., 2004). The basis of
this assay is that any protein of interest has a characteristic
melting temperature because of its intrinsic secondary and
tertiary structure, which could be stabilized or destabilized
upon ligand binding. This effect is usually reflected by the shift
of the melting temperature of the target protein. Sypro orange,
an environmentally sensitive fluorescent dye, could be used to
monitor the protein-unfolding transition. The 95 compounds ob-
tained from HTS were further tested using this method. Most
compounds were either able to increase or decrease the melting
temperature of MgrA (data not shown), indicating that these
compounds disrupt MgrA-DNA interaction mostly by interacting
with the protein rather than intercalating into DNA. Of these, four
prominent compounds are listed in Table 1. MDSA, reminiscent
of a dimerized salicylic acid, displayed the strongest inhibitory
effect on MgrA with an IC50 close to 8.0 mM, according to the
FA assay and the electrophoretic mobility shift assay (EMSA)2011 Elsevier Ltd All rights reserved 1033
Table 1. The Structures of Representative MgrA Inhibitors
Revealed by FA-HTS and FA-Thermal Shift Assay






IC50 of each compound was determined by fluorescence anisotropy
assay and validated by EMSAs (Figure S3). The melting temperature shift
(DT) is presented as a mean value from two independent experiments
(Figure S2). See also Figures S2 and S3.
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Small Molecules Inhibit MgrA(Figure 2). In the thermal shift experiment, this compound was
capable of increasing the melting temperature of MgrA by
7.7C (Figure S2). The other three compounds 2, 3, and 4 fall
into the same class of molecule, 3-aryl-3-(2,5-dimethyl-1H-
pyrrol-1-yl) propanoic acid, and only differ at the aromatic
substituent at the 3 position. All three compounds exhibited
good inhibition activities on MgrA, with IC50 values ranging
from 28 mM to 32 mM. In the thermal shift assay, these three
compounds increased the melting temperature of MgrA by
approximately 2–3C (Figure S2), indicating that they might
interact with MgrA in a very similar manner. The activity of these
compounds to block DNA binding by MgrA was further
confirmed by EMSAs (Figures 2B; Figure S3). MgrA was shown
to be dissociated from its cognate DNA (hla promoter region) in
the presence of these small molecules. Consistent with the FA
and thermal shift assays, EMSA also showed that MDSA was
the most effective compound to disrupt the DNA binding of
MgrA, which prompted us to further investigate this compound.MDSA Alters the Expression of Virulence Factors
in an MgrA-Dependent Manner
MgrA is a global transcriptional regulator that controls expres-
sion of a number of virulence factors, such as genes encoding
a-toxin (hla) and protein A (spa) (Ingavale et al., 2005). MgrA
has been shown to positively regulate the expression of hla by
binding to its promoter region (Ingavale et al., 2005). To test
whether MDSA could abolish the binding of MgrA to the hla
promoter, EMSAs were performed in the presence of different
amounts of MDSA. As shown in Figure 2B, 8 mM of MDSA
could significantly attenuate the binding of MgrA to the hla pro-
moter. The presence of MDSA could also alter the expression
level of both hla and spa inside S. aureus strain Newman. As1034 Chemistry & Biology 18, 1032–1041, August 26, 2011 ª2011 Elshown in the Northern blotting assays (Figure 2C), the expres-
sion level of hla in the wild-type Newman was greatly decreased
in the presence of 0.2 mM of MDSA. Because MgrA acts as an
activator of hla, mutation ofmgrA led to a decreased hla expres-
sion as expected. The expression of hla inmgrAmutant was not
affected by the presence of MDSA, even up to 0.5 mM, strongly
suggesting that MDSA affects the expression of hla in an MgrA-
dependent manner. In addition to the strain Newman, the inhibi-
tion of MDSA on the expression of hla was also observed in the
MRSA strain USA300 according to western blot analysis (Fig-
ure S4). MgrA is known to act as a repressor of the spa gene
(Ingavale et al., 2005). As shown in Figure 2C, the treatment of
wild-type bacteria with MDSA resulted in the increased expres-
sion of spa, whereas in themgrAmutant strain, the expression of
spa occurred at a higher level and was not affected by the pres-
ence of 0.5 mM of MDSA. Taken together, we have demon-
strated that MDSA exerts inhibitory effects on MgrA inside
bacteria, thus leading to the altered expression of the mgrA
regulon.
Binding of MDSA to MgrA
Because we have previously solved the crystal structure of MgrA
(Chen et al., 2006), computational molecular docking (AutoDock
Vina, vina.scripps.edu) was applied to investigate the possible
mode of MDSA binding to MgrA. After running the program,
two possible binding sites (a and b) were revealed, and both
were equally energetically favored (Figure 3A). Interestingly,
both sites are close to the helix-turn-helix DNA-binding motif
that is highly conserved among the MarR/SarA family protein
(Alekshun et al., 2001), implying that MDSA interacts with the
DNA-binding domain of MgrA to interrupt its DNA binding. The
docking structure also reveals that MgrA bears a single Trp48
residue that is located 20.3 A˚ and 20.4 A˚ away from the
a and b sites, respectively (Figure 3A). Because MDSA is a fluo-
rescent compound with excitation at 310 nm and emission at
421 nm, we envision that if MDSA does bind to either the a or
b position, Fo¨rster resonance energy transfer (FRET) should
occur between the donor Trp48 (excitation at 278 nm and emis-
sion at 330 nm) and the acceptor MDSA. To test our hypothesis,
we measured the fluorescence of MgrA in the presence or
absence of MDSA. As shown in Figure 3B, MgrA (10 mM) dis-
played themaximum fluorescent signal at 330 nm in the absence
of MDSA. With the addition of MDSA, the peak at 330 nm, corre-
sponding to the emission of Trp48, was decreased, whereas the
emission of MDSA at 421 nm was elevated. Because the emis-
sion intensity at 330 nm depends on the molar ratio of MgrA-
MDSA versus MgrA, the binding affinity of MgrA to the small
molecule could be estimated through this measurement (Kd =
12.8 mM) (Figure 3C). We consider this value a more accurate
determination of the binding affinity of MDSA to MgrA.
Far-UV (190–250 nm) circular dichroism (CD) spectroscopy is
widely used for monitoring protein secondary structure, whereas
near-UV CD spectroscopy is used for comprehending tertiary
structure (Beychok, 1966; Greenfield, 2006). To investigate
whether the binding of MDSA to MgrA elicits a conformational
change, near-UV (250–320 nm) circular dichroism (CD) spectros-
copy was used. As shown in Figure 3D, molar ellipticity of MgrA
(0.12 mM) was increased slightly at 262 nm but decreased at
285 nm because of the presence of MDSA (0.3 mM), indicatingsevier Ltd All rights reserved
Figure 2. MDSA Inhibits DNA Binding of MgrA
(A) An FA-based binding assay shows dissociation of
MgrA (1 mM) from DNA (0.01 mM) induced by MDSA (IC50
8.0 mM).
(B) EMSA confirming that MDSA induces dissociation of
MgrA (0.5 mM) from its cognate DNA. 32P-labeled DNA
PCR-amplified from the hla promoter region was used.
(C) Northern blot analysis showing that MDSA alters the
expression of virulence factors (spa and hla) regulated by
MgrA; 5 mg of total cellular RNA was used, and the
ethidium bromide–stained gel of the loaded RNA sample is
shown below.
See also Figure S4.
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of MgrA.
SAR Studies of MDSA
Multiple MarR/SarA family proteins, including the Escherichia
coli MarR, E. coli EmrR, Methanobacterium thermoautotrophi-
cum MTH313, and Salmonella typhimurium SlyA, have been
shown to contain potential salicylate-binding sites; however,
salicylate associates with these proteins and attenuates their
DNA binding only at very high concentrations (e.g., at mM level
for MarR) (Martin and Rosner, 1995; Perera and Grove, 2010).
Because MDSA appears to be a dimerized salicylate, it is impor-
tant to ask whether salicylate itself could disrupt the MgrA-DNA
interaction. UnlikeMDSA that can abolish theMgrA-DNA binding
at8 mM, up to 250 mM of salicylate showed almost no effect on
the DNA binding of MgrA, as shown in Figure 4, indicating that
dual phenolic moiety is imperative for the function of MDSA.
We tested other modifications. The treatment with 250 mM of
3, 30-dimethylenebenzoic acid 6, which lacks the OH group at
aromatic ring, was unable to dissociate MgrA from DNA, sug-
gesting that the hydroxyl group is required for the binding. The
COOH group is also required for binding; the dimethyl ester of
MDSA cannot disrupt the binding of MgrA to DNA. The confor-
mation of MDSA is crucial to its interaction with MgrA. As shown
in Figure 4, Olsalazine 8, an anti-inflammatory medicine that is
structurally analogous to MDSA but has a rigid trans configura-
tion, could not affect the DNA binding of MgrA at 250 mM level.
Collectively, all the structural features of MDSA aswell as its flex-
ible conformation are required for its ability to disrupt MgrA-DNA
interaction.
MDSA Changes the Susceptibility of S. aureus
to Antibiotics
MgrA negatively regulates the expression of efflux pumps in-
cluding Tet38, NorA, NorB, and NorC, which account for bacte-Chemistry & Biology 18, 1032–1041, August 26,rial resistance to multiple antibiotics such as
tetracycline, norfloxacin, and ciprofloxacin
(Kaatz et al., 2005; Truong-Bolduc et al., 2005;
Truong-Bolduc et al., 2006). MgrA is also shown
to affect bacterial resistance to vancomycin
(Chen et al., 2006; Trotonda et al., 2009;
Truong-Bolduc and Hooper, 2007). Mutation of
mgrA leads to increased resistance of the
bacterium to these antibiotics. Therefore,
MDSA should alter staphylococcal resistanceto these antibiotics if it does exert inhibitory effects on MgrA
inside S. aureus. As shown by the plate sensitivity assay in Fig-
ure 5, in the absence of MDSA, themgrAmutant strain displayed
stronger resistance to vancomycin (1.2 mg/ml), compared to the
wild-type Newman, as expected. The phenotype can be com-
plemented with pYJ335-mgrA, which restores vancomycin
susceptibility to the wild-type level. In the presence of MDSA
(0.2mM), both the wild-type and complementary strain exhibited
an increased vancomycin resistance that is comparable to the
mgrA mutant strain, implying that MgrA is inhibited in both
strains. Similar effects were observed on the plates containing
fluoroquinolones (norfloxacin [0.8 mg/ml] and ciprofloxacin
[0.3 mg/ml]); the wild-type Newman was more susceptible to
fluoroquinolones than the mgrA mutant in the absence of
MDSA, whereas the growth inhibition of the wild-type Newman
caused by norfloxacin or ciprofloxacin was alleviated on the
plate containing 0.2 mM of MDSA. The complementary strain
carrying pYJ335-mgrA showed hypersensitivity toward both
norfloxacin and ciprofloxacin, probably because of the elevated
level of exogenous mgrA under this particular condition.
Measurements of minimum inhibition concentration (MIC) for
these antibiotics (vancomycin, norfloxacin, and ciprofloxacin)
further confirmed our observation from the plate sensitivity
assays. As shown in Table S1, the wild-type Newman showed
greater resistance toward vancomycin, norfloxacin, and cipro-
floxacin in the presence of MDSA (0.2 mM) than its absence,
whereas the antibiotic resistance of its mgrA mutant was not
affected by MDSA. In addition to the strain Newman, the mgrA
mutant of USA300 also showed increased resistance toward
vancomycin in comparison to the wild-type USA300. Similar to
Newman, MDSA (0.2 mM) increased the vancomycin resistance
of the wild-type USA300, but not its mgrA mutant (Table S1).
Although the resistance of USA300 toward ciprofloxacin or nor-
floxacin appears to be unaffected by the mutation ofmgrA, both
of which showed equal resistance (Table S1), the presence of2011 ª2011 Elsevier Ltd All rights reserved 1035
Figure 3. Binding Assays of MDSA to MgrA
(A) Docking models of MDSA binding to MgrA. Molecular
docking experiment indicates two plausible binding sites
(a and b) forMDSA. The distance between a site and Trp48
is 20.3 A˚. The distance between b site and Trp48 is 20.4 A˚.
(B) FRET generated between Trp48, the only Trp in the
MgrA sequence, and the bound MDSA. Excitation was at
278 nm. Emission of Trp48 in MgrA was at 330 nm.
Emission of MDSAwas at 421 nm. The fluorescence of the
Apo-MgrA (1 mM) was shown in black. FRET experiments
were shown in colored bands.
(C) A binding curve of MDSA to MgrA obtained from the
FRET experiment; 1 mM MgrA was used. The concentra-
tion of MDSA varies from 64 mM to 2 mM. Shown are the
mean and standard deviation of three independent ex-
periments.
(D) The near-UV (250–320 nm) CD spectrum of MgrA
(0.12 mM) in the absence or presence of MDSA (0.3 mM).
Apo-MgrA is shown in yellow. The MgrA-MDSA complex
is shown in pink.
See also Figure S7.
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resistance of not only the wild-type USA300 but also its mgrA
mutant, implying the existence of a possible mgrA-independent
pathway affected by MDSA in USA300. Overall, the intrinsic
resistance of the mgrA mutant of either the strain Newman or
USA300 to antibiotics was less affected by MDSA, indicating
that MDSA affects S. aureus antibiotic resistance via an mgrA-
dependent pathway. Together, the data suggest that MDSA
inhibits MgrA inside S. aureus, thereby affecting functions regu-
lated by MgrA.
MDSA Attenuates S. aureus Virulence in the Mouse
Model of Abscess Formation
Because most virulence factors play nonessential roles in the
in vitro growth of S. aureus, we envision that the small molecule
designed for virulence suppression should not affect the viability
of S. aureus under normal conditions, yet it should suppress
in vivo pathogenesis of S. aureus. As shown in Figures S5 and
S6, S. aureus displayed no growth defect in the presence of up
to 10 mM of MDSA. We next employed a mouse model of
abscess formation to test the potential virulence suppression
function of MDSA. The diacid form of MDSA could suffer from
an absorption/distribution (AD) problem once entering the
mouse body. Specifically, the negative charge may prevent the
molecule from efficiently crossing the tissue-blood barrier to
reach infection sites. Previous pharmacokinetic (PK) studies on
methyl-salicylate (esterified salicylate) have revealed that methyl
salicylate maintains an extremely high permeability through
blood-brain barrier and blood-tissue barrier while undergoing
rapid and efficient hydrolysis inside animal tissues (Finkel et al.,
2009). The liver was shown to be the major site of methyl salicy-
late hydrolysis (Davison et al., 1961). Because MDSA has high
structural similarity to salicylate, we synthesized the dimethyl
form 7 of MDSA and envisioned that hydrolysis of 7 in the liver
or kidney would lead to accumulation of MDSA, which in turn
could potentiate its antistaphylococcal activity inside these
organs. To test this idea, we simultaneously injected S. aureus
and 7 into mice via the retro-orbital route. After 4 days, we
observed attenuated abscess formation in kidneys and livers1036 Chemistry & Biology 18, 1032–1041, August 26, 2011 ª2011 Elfrom mice coadministered with the compound. The number of
colony-forming units (CFUs) in the corresponding organs
including livers and kidneys was only 10% of that from mice
without treatment (Figure 6). Collectively, these data demon-
strate that MDSA is able to prevent S. aureus infection in the
mouse. Future modifications may improve the in vivo potency.
DISCUSSION
Amajor challenge facing contemporary medicine is the develop-
ment of new antibiotics against human pathogens that are
resilient to most current antimicrobial therapies (Borlee et al.,
2010; Clatworthy et al., 2007; Park et al., 2007; Rainey and
Young, 2004; Skaar, 2010; Stringer et al., 2010; Swoboda
et al., 2010; Wright et al., 2005). It has been well documented
that S. aureus has developed multiple resistance mechanisms
against almost all known antibiotics, a problem that urgently
requires identification of new therapeutic targets and develop-
ment of alternative strategies for combating S. aureus (Fridkin
et al., 2005; Lowy, 1998; Walsh, 1993; Weigel et al., 2003).
MgrA, a member of the MarR/SarA family transcriptional regula-
tors that controls the expression ofmany virulence determinants,
is essential for staphylococcal virulence in animal model exper-
iments. Therefore, inhibition of the function of MgrA is of great
therapeutic potential.
Virulence regulators are promising targets for developing
novel antibiotics. However, targeting virulence regulation has
not been fully exploited, and only a limited number of examples
are present so far (Gauthier et al., 2005; Hung et al., 2005). In
Vibrio cholerae, an inhibitory small molecule (e.g., virstatin) ob-
tained through HTS has been found to disrupt the dimerization
and function of ToxT, a virulence transcriptional regulator,
thereby preventing the expression of several critical virulence
factors in V. cholerae (Shakhnovich et al., 2007). To our knowl-
edge, the strategy of using a small molecule to target transcrip-
tional regulators has yet to be applied to S. aureus. Our study
represents an early success that demonstrates virulence sup-
pression in S. aureus by targeting the MgrA regulator with small
molecules.sevier Ltd All rights reserved
Figure 4. Structure and Activity Relationship (SAR) Studies of MDSA
Four derivatives (salicylic acid 5, 3, 3-methylenedibenzoic acid 6, methyl 5,
5-methylenedisalicylate 7, and Olsalazine 8) of MDSA are unable to disrupt the
MgrA-DNA interaction at concentrations of up to 250 mM.
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Small Molecules Inhibit MgrAStructurally, MDSA is a reminiscent of salicylic acid, a preva-
lent plant hormone that has been shown to affect S. aureus in
many aspects (Riordan et al., 2007). Previous studies have
showed that salicylate induces increased staphylococcal resis-
tance to multiple antimicrobials, such as the DNA topoisomer-
ase inhibitor fluoroquinolones (ciprofloxacin and norfloxacin),
the protein synthesis inhibitor fusidic acid, and the DNA-interca-
lating dye ethidium (Gustafson et al., 1999; Price et al., 2002).
Unlike salicylate which reduces the growth of S. aureus at
2 mM (Riordan et al., 2007), even 10 mM of MDSA does not
inhibit growth of different S. aureus strains tested (Figure S5).
Although salicylate has been shown to down-regulate the
expression of transcription factors mgrA and sarR while up-
regulating sarA transcription (Gustafson et al., 1999), our
EMSA indicated that a high concentration (250 mM) of salicylate
has little effect on the DNA-binding activity of MgrA, which
excludes the possibility that salicylate alters mgrA transcription
through directly interfering its autoregulation (Ingavale et al.,
2003).
The small-molecule MDSA might inhibit the DNA binding of
MgrA via two possible modes. Because MgrA functions as
a dimer, MDSAmight disrupt the dimerization ofMgrA. However,
our gel filtration analysis showed that even 1 mM of MDSA was
unable to change the dimeric status of MgrA (Figure S7), which
excludes this possibility. The other possibility is that MDSAChemistry & Biology 18, 1032–directly perturbs the DNA-binding domain of MgrA. Our compu-
tational docking experiment has indicated that MgrA bears two
possible binding sites for MDSA around its DNA-binding lobe
(the HTH motif). This hypothesis was supported by the FRET
experiment that showed close proximity of the MgrA-bound
MDSA to Trp48 nearby. Potentially, MDSA binds the DNA-
binding HTH motif of MgrA, which alters its conformation, thus
disrupting DNA binding of MgrA.
Protein-DNA interaction is central to transcriptional regulation
in biology. Despite a growing number of examples of small
molecules targeting transcription (Chau et al., 2005; Darnell,
2002; Dervan et al., 2005; Kiessling et al., 2007; Lauth et al.,
2007; Lu et al., 2005; Rishi et al., 2005; Vassilev et al., 2004),
the process of identifying effective small molecules that exhibit
activity inside cells is still challenging. In very few examples
have small molecules been identified that effectively disrupt
protein-DNA interactions. We show here that MDSA is able to
disrupt MgrA-DNA interaction and further attenuate staphylo-
coccal virulence expression. The MarR/SarA family proteins
present excellent targets because they have long been estab-
lished as transcription regulators responsive to environmental
stimuli such as small molecule ligands, ROS, and pH (Perera
and Grove, 2010; Wilkinson and Grove, 2006), of which the
intrinsic conformational flexibility and the existence of ligand-
binding pocket provide the opportunity to identify inhibitors
that can bind these proteins and disrupt regulatory function. It
has been recognized that most MarR/SarA proteins comply
with a two-state model (Perera and Grove, 2010): the apo-
protein compatible with DNA binding and the modified form
incompatible with DNA binding owing to ligand binding, or post-
translational modifications (PTS), such as oxidation and phos-
phorylation (Didier et al., 2010; Truong-Bolduc et al., 2008;
Truong-Bolduc and Hooper, 2010). Given that MgrA is sub-
jected to multiple PTSs, such as oxidation of Cys12 and phos-
phorylation at Ser/Thr (Chen et al., 2006; Truong-Bolduc et al.,
2008), the binding of MDSA to MgrA might trigger a similar
conformational change and preconfigure the protein into the
second state that is incompatible with DNA binding. Future
study will focus on structurally elucidating the mode of action
of MDSA to gain further insight into tuning the function of
MgrA with small molecules.
SIGNIFICANCE
MgrA is a global transcriptional regulator essential for the
pathogenesis of S. aureus. It provides a potential drug target
for combating staphylococcal infections. In this study, we
identified a small-molecule MDSA that inhibits DNA binding
of MgrA through a high-throughput screening. MDSA alters
the transcriptional expression of virulence factors, including
hla and spa, both of which are known to be regulated by
MgrA. MDSA also affects bacterial antibiotic resistance
toward vancomycin, norfloxacin, and ciprofloxacin via an
mgrA-dependent pathway. Simultaneous administration of
esterified MDSA with S. aureus could attenuate S. aureus
virulence, as demonstrated in a mouse model of infection.
This study demonstrates that small molecules can be devel-
oped to disrupt protein-DNA interactions of transcriptional
regulators as a strategy to combat bacterial infection.1041, August 26, 2011 ª2011 Elsevier Ltd All rights reserved 1037
Figure 5. Effects of MDSA on Staphylo-
coccal Antibiotic Susceptibility toward Van-
comycin, Norfloxacin, and Ciprofloxacin
The antibiotic resistance levels were tested in the
presence or absence of MDSA (200 mM) by a plate
sensitivity assay; 10 ml of mid-log culture was
diluted 1000-fold in PBS before plating in dupli-
cate. Van, vancomycin (1.2 mg/ml); Nor, nor-
floxacin (0.8 mg/ml); Cip, ciprofloxacin (0.3 mg/ml).
See also Table S1.
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Unless stated otherwise, all chemicals were purchased from Sigma-Aldrich,
and the restriction enzymes were purchased from New England Biolabs.
Because all assays were performed under physiological conditions (pH 7.4),
compound MDSA was always used in the form of disodium salt unless
otherwise noted. Other organic compounds were dissolved in DMSO for
biochemical and biological assays.
Ethics Statement
The animal study presented in this report (Approval ID: NW-20) was approved
by the Institutional Animal Care and Use Committee at Indiana University
School of Medicine-Northwest, which complies with the guidelines of the
National Institutes of Health.
Bacterial Strains, Plasmids, and Culture Conditions
The bacterial strains used in this study are listed in Table S2. Unless otherwise
mentioned, S. aureus strain Newman is the strain used in the study. S. aureus
cells were grown in tryptic soy broth (TSB). For routine culture of mgrA trans-
poson mutants, erythromycin (10 mg/ml) was added, while chloramphenicol
(10 mg/ml) was added to mgrA mutant complemented with pYJ335-mgrA.
Expression and Purification of the MgrA Protein
The expression and purification of His6-MgrA have been described previously
(Chen et al., 2006). Briefly, E. coli (BL21star (DE3)) carrying pet28a::mgrA in LB
was grown at 37C. After reaching mid-log phase (OD600, 0.6), cells were
induced with 1 mM of IPTG for 4 hr at 30C. Cells were harvested and stored
at 78C before use. MgrA was purified by Ni-NTA column following the
manufacture’s manual (GE Healthcare). The purity of MgrA was determined
by SDS-PAGE. Protein was desalted to remove imidazole before subsequent
biochemical assays.
Oligonucleotide Synthesis
The oligonucleotide (50-6-F-TAAACAACAAGTTGTCCAAA-30 ) containing
6-carboxylfluorescein was prepared by incorporating the 50-fluorescein phos-
phoramidite (6-FAM) (Glen Research, Inc.) at the 500 end during solid-phase
synthesis. The resulting oligonucleotide was purified with denaturing poly-
acrylamide gel electrophoresis. The labeled oligonucleotide was annealed
with its complementary strand and then used for FA-based binding assays.
FA–Based Binding Assays
To determine the binding affinity ofMgrA to the labeled DNA, different amounts
of MgrA, varying from 0.0015 mM to 6.0 mM,were added into the 96-well format
plate containing 20 nM DNA, 10 mM Tris (pH, 7.4), and 25 mM NaCl. The
Envision plate reader (475 nm/525 nm) was used to measure FA values. The
Kd value was calculated using Microsoft Excel. The measurements were
done in triplicate.1038 Chemistry & Biology 18, 1032–1041, August 26, 2011 ª2011 Elsevier Ltd All rights reseScreen of MgrA Inhibitors
A high-throughput screen (HTS) of compound
libraries to identify MgrA inhibitors was performed
at The National Screening Laboratory for the
Regional Centers of Excellence in Biodefense
and Emerging Infectious Disease (NSRB) at Har-
vard Medical School. The MgrA protein (700 nM,30 mL) was added to the black polystyrene 384-well plate, except column
24, to which 30 ml of empty control buffer (10 mM Tris [pH 7.4] and 25 mM
NaCl) was added. Test compounds (10 ng in 1 mL) were added into each
well except columns 23 (negative controls) and 24. The solution was incubated
at room temperature for 20min. Then 20 mL of DNA solution (50 nM)was added
to all wells and the mixtures were incubated for another 20 min. The Envision
plate reader (475 nm/525 nm) was used to detect FA values. For hit selections,
we set up the cut-off range minus positive control (column 24) plus 50%
of dynamic range (column 23 minus 24). Ninety-five compounds out of
88,564 were cherry-picked for further validation and characterization.
Fluorescence-Based Thermal Shift Assays
The thermal shift assay was conducted as previously described (Lo et al.,
2004). The fluorescent dye Sypro orange (Sigma), an environmentally sensitive
fluorophore, was used to monitor the unfolding of MgrA. The basis of this fluo-
rescence-based thermal shift assay is that the protein unfolding exposes
Sypro orange to a hydrophobic environment, leading to increased fluores-
cence of Sypro orange. This assay was performed in the iCycler iQ Real
Time PCR Detection System (Bio-Rad). Solutions of 20 ml of MgrA (final
concentration, 5 mM), 50 ml of 5X Sypro orange, 2 ml of compound (20 ng),
and 28 ml of buffer (100 mM NaCl and 10 mM Tris [pH 7.4]) were added to
the wells of the 96-well iCycler iQ PCR plate. The plate was heated from
25C to 77C with a heating rate of 0.5C/min. The fluorescence intensity
was measured with Ex/Em: 490 nm/530 nm. Ninety-five compounds from
cherry picks were tested in duplicate. The data were processed as previously
described (Lo et al., 2004).
FRET Measurement of Small Molecule Binding to MgrA
Various amounts of MDSA ranging from 64 mM to 2 mM were added to the
buffer (100 mM NaCl and 10 mM Tris [pH 7.4]) containing 1 mM of MgrA. The
change of fluorescence was monitored at 330 nm (MgrA) and 421 nm
(MDSA), respectively. Excitation was set at 278 nm.
Circular Dichroism Spectrometry
TheMgrA protein (0.12mM)was incubated with 0.3mMofMDSA in PBS buffer
at 25C for 10 min. Near-UV region (250–350 nm) CD spectrum was measured
at 25C by AVIV 202 CD Spectrometer (AVIV Biomedical Inc.). The protein
sample without the small molecule was also tested as a comparison.
Synthesis of Compound 7
Compound 7 was obtained according to literature methods (Cameron et al.,
2002; Guo et al., 2005). Briefly, MDSA (1 g) was dissolved in 20 ml of methanol
and then 1 ml of HCl (10 M) was added. The mixture was stirred and refluxed
at 70C overnight. The resulting product was isolated with silica gel column.
Electrophoretic Mobility Shift Assays
DNA probe was PCR amplified from the hla promoter region with primers listed
in Table S3. DNA was labeled with 32P at the 50 end using T4 polynucleotiderved
Figure 6. Coadministration of theDimethyl EsterMDSA 7Attenuates
Staphylococcal Virulence in a Murine Abscess Model
The test strains (1 3 107 CFU) mixed with and without compound 7 were
administered into 16 mice per strain via retro-orbital injection. Four days later,
after measuring weight losses, organs were harvested and bacterial CFU in the
organs was measured by the serial dilution method. In the graph, each dot
represents a mouse. The group not treated with small molecule is indicated as
‘‘WT.’’ The group treated with small molecule is indicated as ‘‘15 mg/kg.’’ The
statistical difference was determined by Student’s two-tailed t test. See also
Figures S5 and S6.
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Small Molecules Inhibit MgrAkinase (Promega). MgrA (0.4 mM) was incubated with various amounts of test
compounds and 2 ng of radioactive DNA probe in 25 ml of the binding buffer
(10 mM Tris-HCl [pH 7.4], 50 mM KCl, 5 mM MgCl2, 10% glycerol, and
3 mg/ml sheared salmon sperm DNA). After 10 min at room temperature, the
samples were analyzed by 8% native polyacrylamide gel electrophoresis
(100 V for pre-run, 85 V for 85 min for sample separation). The gels were dried
and subjected to autoradiography on a phosphor screen (BAS-IP, Fuji).
RNA Isolation and Northern Blotting
To isolate the RNA for Northern blot analysis, all S. aureus strains were grown
at 37C overnight in tryptic soy broth (TSB), diluted 100-fold in fresh 10ml TSB
containing various amounts of MDSA (0, 200 mM, 350 mM, and 500 mM) in
a 50-ml conical tube (BD Biosciences), and incubated at 37C with shaking
at 250 rpm for 2.5 hr (OD600, 0.8). Cells were harvested and disruptedmechan-
ically (Fast Prep FP120 instrument; Qbiogene, Heidelberg, Germany). The
RNeasy Mini Kit (QIAGEN) was used for the subsequent RNA purification.
RNA concentration and purity were determined by UV absorption at 260 and
280 nm. Northern blotting was performed following previously reported proce-Chemistry & Biology 18, 1032–dures (Lan et al., 2010). Primers used for amplification of DNA fragments in
Northern blotting are listed in Table S3.
Antibiotic Susceptibility Assays
Minimum inhibitory concentration (MIC) was determined by the microdilution
method in 96-well plates. Antibiotics were serially diluted twofold in 100 ml of
LB. Overnight cultures were diluted with 13 PBS to cell density of 107 CFU/ml.
To each well of the 96-well plate, aliquots of 5 ml were added for a final inoc-
ulum of approximately 5 3 104 CFU/well. After incubation at 37C for 24 hr,
the MICs were determined visually.
Plate Sensitivity Assays for Antibiotic Resistance
TSA plates were made with designated amounts of MDSA and the antibiotic
(vancomycin, ciprofloxacin, or norfloxacin). The overnight culture was diluted
by 100 fold into fresh TSB containing 0.2 mM of MDSA. After 3 hr at 37C, the
mid-log culture was diluted by 1000 fold in PBS. Aliquots (10 ml) of the diluted
cultures for each strain were spotted onto the solid media and grown at 37C
for 24 hr. Each experiment was repeated at least three times to ensure
consistency.
Mouse Models of Abscess Formation
This assay was performed as described previously (Chen et al., 2006) with
slight modifications. To determine the effect of MDSA on the virulence of
S. aureus, its esterified derivative 7 was used. After measuring the weight of
the mice, 1 3 107 CFU of the wild-type Newman strain in PBS mixed with/
without small molecules (0.3 mg, the final concentration is 10 mM in the cell
culture) were administered to 16 Balb/c mice (Harlan, USA) via retro-orbital
injection. The average body weight of mice is 20 g. Four days after the injec-
tion, the mice were sacrificed and their organs (kidney and liver) were har-
vested. The harvested organs were homogenized; then the CFU of bacteria
in the organs were measured using serial dilutions on TSA plates. A Student’s
t test was performed to evaluate the statistical significance of the data by using
Microsoft Excel. As a control experiment to ensure that the same dose of small
molecules did not affect bacterial fitness in vitro, the same cell cultures in PBS,
after being treatedwith these compounds for 1 hr at 37C, were plated on TSA.
No growth defects were observed compared to the culture not treated with
small molecules.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, three tables, and Supple-
mental Experimental Procedures and can be found with this article online at
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